These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 8486570

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U, Manncke B, Gerbracht K, Werner H.
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C, Sánchez A, Gómez M, Palau ML, Picazo JJ.
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [Abstract] [Full Text] [Related]

  • 5. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ, Hsueh PR, Tsai JC, Liaw SJ, Ho SW, Luh KT.
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [Abstract] [Full Text] [Related]

  • 6. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
    Rezvan SP, Sidorenko SV, Budanov SV.
    Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
    [Abstract] [Full Text] [Related]

  • 7. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [Abstract] [Full Text] [Related]

  • 8. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B, Naden M.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
    Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
    [Abstract] [Full Text] [Related]

  • 10. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
    Falagas ME, McDermott L, Snydman DR.
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2047-9. PubMed ID: 9303414
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
    Stratton CW, Weeks LS, Aldridge KE.
    Diagn Microbiol Infect Dis; 1992 Sep; 15(4):321-30. PubMed ID: 1611847
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE, Lindmark A, Persson I.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [Abstract] [Full Text] [Related]

  • 13. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W, Pitkin DH, Nadler H.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR, Niles AC.
    Diagn Microbiol Infect Dis; 1990 Jun; 13(1):57-61. PubMed ID: 2331851
    [Abstract] [Full Text] [Related]

  • 15. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.
    Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE.
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1238-43. PubMed ID: 11257040
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of L-627 against anaerobic bacteria.
    Nord CE, Lindmark A, Persson I.
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):757-60. PubMed ID: 1425740
    [Abstract] [Full Text] [Related]

  • 17. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea.
    Roh KH, Kim S, Kim CK, Yum JH, Kim MS, Yong D, Lee K, Kim JM, Chong Y.
    Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC, Gottlieb T, Palmer JM, Morris G, Gilbert GL.
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [Abstract] [Full Text] [Related]

  • 19. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR, Jacobus NV, McDermott LA.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
    Aldridge KE, Morice N, Schiro DD.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):889-93. PubMed ID: 8031067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.